Sutro Biopharma, INC.: directors' dealings · United States · SEC (Form 4)

About Sutro Biopharma, INC.

Sutro Biopharma, Inc. (ticker: STRO) is a U.S.-listed biotechnology company trading on NASDAQ in the United States, with headquarters in South San Francisco, California. Founded in 2003 under the original name Fundamental Applied Biology, Inc. and later renamed Sutro Biopharma, the company has built its identity around next-generation oncology innovation. Its core technological foundation is the proprietary cell-free protein synthesis platform XpressCF® paired with the site-specific conjugation platform XpressCF+®, which together are designed to enable the discovery and manufacturing of more homogeneous, potentially more differentiated antibody-drug conjugates (ADCs). Sutro’s business is primarily focused on the development of oncology assets, while also monetizing its platform through selective partnerships with pharmaceutical and biotechnology companies. The company’s historical significance comes from its ability to generate internally discovered programs, including STRO-001 and STRO-002 (luvelta), which helped validate its technology and demonstrated the breadth of the platform. In recent periods, Sutro has sharpened its strategic focus around a more concentrated pipeline, with STRO-004 as its highest-priority wholly owned asset, alongside additional programs such as STRO-006 and STRO-227 moving through preclinical and regulatory-enabling work. From a competitive standpoint, Sutro operates in the highly contested ADC market, where differentiation depends on payload design, target selection, tolerability, manufacturability, and clinical execution. The company’s investment case is based on the idea that its site-specific and novel-format ADC approach can generate better therapeutic profiles and a more scalable manufacturing process than conventional stochastic conjugation methods. That said, it remains a clinical-stage biotech with the usual risks: clinical readouts may disappoint, regulatory timelines can shift, and financing needs can affect shareholder dilution. Geographically, Sutro is largely U.S.-based, with its corporate and research footprint rooted in California, but its commercial and scientific ambitions are global because oncology development, trial recruitment, and partnering are international in nature. Recent developments have centered on the continued advancement of the pipeline, including ongoing Phase 1 work for STRO-004, IND-enabling activity for STRO-006 and STRO-227, and recent quarterly and full-year financial updates in 2025 and 2026. The company also completed a significant equity financing in early 2026 to strengthen its balance sheet and extend operating visibility. For French-speaking investors, STRO should be viewed as a high-risk, high-upside biotech story: scientifically interesting, strategically focused, but still dependent on clinical delivery and capital discipline.